Anti-IL-23a Reference Antibody (risankizumab) is a recombinant monoclonal antibody designed for research use, mimicking the binding and neutralizing activity of risankizumab against interleukin-23 (IL-23). It targets the p19 subunit of IL-23, a key cytokine in inflammatory pathways, and is used in in vitro assays, preclinical studies, and bioanalytical method development to investigate IL-23 signaling inhibition.

This reference antibody supports research into immune-mediated diseases such as plaque psoriasis, psoriatic arthritis, and Crohn's disease by enabling the evaluation of therapeutic candidates that block IL-23 pathways. It is not intended for clinical therapeutic use but provides a standardized tool for immunological research with high specificity and affinity comparable to the therapeutic biologic.